Ustekinumab treatment in children with refractory Crohn′s disease: six cases and literature review
10.3760/cma.j.cn101480-20240108-00007
- VernacularTitle:乌司奴单克隆抗体治疗儿童难治性克罗恩病六例分析并文献复习
- Author:
Tianlu MEI
1
;
Shu GUO
;
Xiaolin YE
;
Dongdan LI
;
Jie WU
Author Information
1. 国家儿童医学中心 首都医科大学附属北京儿童医院消化科，北京 100045
- Publication Type:Journal Article
- Keywords:
Crohn′s disease;
Children;
Ustekinumab;
Refractory;
Biologic
- From:
Chinese Journal of Inflammatory Bowel Diseases
2024;08(3):223-229
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy and safety of ustekinumab (UST) in the treatment of refractory Crohn′s disease (CD) in children.Methods:The clinical features, diagnosis and treatment of 6 patients with children refractory CD and CD-like monogenic inflammatory bowel disease (IBD) who were treated with ustekinumab (UST) at the Department of Gastroenterology, Beijing Children′s Hospital affiliated to Capital Medical University from August 2021 to January 2023 were retrospectively analyzed. The relevant literatures were reviewed and summarized by searching the articles on the treatment of refractory CD in children with UST published in Wanfang database, CNKI, PubMed and Medline.Results:All the six children with refractory CD and CD-like monogenic IBD were boys. Among them, 1 case was diagnosed as IL-10RA receptor defect, 1 case was diagnosed as IPEX syndrome, and 1 case diagnosed as X-linked lymphoproliferative syndrome (XLP-2) . Two patients were treated with UST only, three patients were treated with UST combined with thalidomide until presented clinical remission, and one patient was treated with UST in combination with IFX. Six children were treated with UST for over 24 weeks, and all of them presented clinical response. After treatment for more than 24 weeks, 4 cases presented endoscopic response.None of the 6 patients had special adverse drug reactions during follow-up for 24 weeks. A total of 16 literatures were retrieved. Conclusion:UST may induce and maintain remission in children with refractory CD.
